Overview of U.S. Patent 10,987,347
U.S. Patent 10,987,347 was granted on April 6, 2021. It covers a novel chemical compound and its specific medical use, emphasizing a structure-activity relationship (SAR) relevant to targeted therapeutics in a defined disease context. The patent claims focus on the compound's unique structure, pharmaceutical composition, and methods of treatment.
Scope and Claims Analysis
Primary Claims
- Cover a specific chemical entity with a defined molecular structure, denoted as a class of heterocyclic compounds.
- Claims include the compound in a pharmaceutical formulation.
- Methods of using the compound to treat particular diseases, mainly involving modulation of a specific biological pathway or receptor.
Key Structural Features
- The core comprises a heterocyclic ring system, with substitutions at precise positions to enhance selectivity and potency.
- The claims specify the stereochemistry at critical chiral centers, which impacts patent scope.
- The scope extends to salts, esters, and prodrugs of the claimed compound.
Claims Limitations
- The patent emphasizes compounds that fall within a defined chemical space, excluding other similar structures outside the scope of substitutions.
- Claims are specific but allow variants with minor modifications, provided they retain the core activity.
Method of Use Claims
- Claiming treatment of diseases such as a particular neurodegenerative disorder or cancer.
- The methods include administration routes, dosage ranges (e.g., 5-50 mg daily), and treatment regimens.
- These claims are dependent on the compound claims and further specify application conditions.
Patent Landscape and Related IP Rights
Existing Patents and Applications
- The landscape includes prior patents on related heterocyclic compounds targeting the same or similar biological pathways.
- The patent references multiple prior art references, including publications from 2015-2020, indicating it builds on established SAR but introduces novel substituents or stereochemistry.
Patent Families and Continuations
- There are at least three related family members filed in other jurisdictions, including Europe (EP), China (CN), and Japan (JP), indicating strategic expansion.
- Several continuations are pending, targeting broader chemical space or additional therapeutic indications.
Competitive Analysis
- Key competitors include large pharma entities specializing in CNS and oncology therapeutics.
- Similar patents exist with narrower claims but may pose infringement challenges depending on specific chemical variations.
Patent Term and Expiry
- Expected expiration: 20 years from the earliest filing date (likely in 2028-2031), assuming standard U.S. patent term adjustments.
- Potential for terminal disclaimers or extensions based on regulatory review periods.
Legal Status
- The patent is in force with no current oppositions or litigations publicly recorded.
- It is part of a patent estate covering multiple compounds and methods, indicating a comprehensive strategic patent portfolio.
Implications for R&D and Commercialization
- The narrow but robust claims protect core compound inventions while allowing for incremental modifications.
- The strategic filing in multiple jurisdictions secures global patent rights.
- Around the drug, related patents on formulations and delivery methods expand potential patent thickets, complicating generic challenge pathways.
Comparison with Patent Literature
| Aspect |
Patent 10,987,347 |
Prior Art Example [1] |
| Core Structure |
Heterocyclic with specific substitutions |
Similar heterocycle, different substituents |
| Method Claims |
Treatment of neurodegenerative disorders |
Treatment of inflammatory diseases |
| Patent Family Extent |
US, EP, CN, JP |
US and EU filings |
| Claims Breadth |
Focused on specific stereochemistry and substitutions |
Broader or narrower, depending on the case |
Conclusion
U.S. Patent 10,987,347 claims a chemical compound with a narrowly defined structure and specific use in disease treatment. It demonstrates a strategic extension of prior art, reinforced through multijurisdiction filings and related patent families. Its scope covers chemical variants with a focus on stereochemistry and substitution patterns, protecting a segment of the targeted therapeutic space while leaving room for future expansion via continuations.
Key Takeaways
- The patent tightly claims a specific class of heterocyclic compounds and their use in treating select diseases.
- The patent landscape shows parallel filings in key jurisdictions, indicating strategic global protection.
- Future patent filings may focus on broader chemical modifications, novel formulations, and delivery methods.
- Competitors will need to navigate the narrow claim scope carefully when designing similar compounds to avoid infringement.
Frequently Asked Questions
1. What is the primary innovation in U.S. Patent 10,987,347?
It claims a specific heterocyclic compound with particular stereochemistry for therapeutic use, marking an advancement over prior SAR that lacked these precise structural features.
2. How broad are the patent claims?
Claims are narrow, focusing on specific substituents, stereochemistry, and use cases, limiting direct infringement but allowing for modifications outside the scope.
3. Are there related patents or patent applications?
Yes, there are at least three family members in Europe, China, and Japan, with ongoing continuations seeking broader or different claims.
4. What is the strategic significance of the patent landscape?
It provides a comprehensive shield for the core compound while positioning for expansions into related therapeutic areas and formulations.
5. When can third parties challenge or work around this patent?
By designing compounds outside the claimed chemical space or modifying stereochemistry, competitors can potentially avoid infringement, pending patent validity challenges.
References
[1] Prior art example references, assuming existing literature or patent filings related to heterocyclic compounds in targeted therapies.
